ArticleEuropean journal of medical research2025
EPDR1 promotes gastric cancer progression via STAT3-mediated fatty acid metabolic reprogramming.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid Accumulation Promotes Tumorigenic Behaviour of Colorectal Cancer Cells.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
EPDR1 has been shown to play critical regulatory roles in development of several types of cancer. Nevertheless, the role of EPDR1, a family of glycoproteins involved in cell-cell contact, to gastric cancer (GC) remain unknown. Here, we determined that EPDR1 is significantly upregulated in GC tissues and cell lines, and is associated with poor prognosis. In vitro and in vivo functional assays demonstrate that EPDR1 promotes the proliferation, migration, and invasion of GC cells. Mechanistically, EPDR1 regulates the expression level of CPT1A, thereby mediating metabolic reprogramming of the fatty acid oxidation pathway. Our RNA immunoprecipitation (RIP) experiments show that CPT1A interacts with STAT3 in GC cell lines, and that EPDR1 mediates the phosphorylation of STAT3 via CPT1A. Overall, our work elucidates that EPDR1 activates the JAK-STAT pathway through the regulation of CPT1A, leading to enhanced phosphorylation of STAT3 and promoting fatty acid oxidation levels in GC, thus facilitating the progression of gastric cancer and providing a potential therapeutic target for its treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.